INTENSITY THERAPEUTICS, INC. Logo

INTENSITY THERAPEUTICS, INC.

Develops injected therapies to kill tumors locally and activate a systemic immune response.

INTS | NDAQ

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
United States of America
Address:
1 ENTERPRISE DRIVE, SUITE 430, 6484 SHELTON
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Intensity Therapeutics, Inc. is a late-stage clinical biotechnology company developing a novel, immune-based approach to treat solid tumor cancers. The company's proprietary DfuseRx℠ technology platform enables the direct intratumoral injection of therapeutic agents. This 'treat locally, act globally' method is designed to kill cancer cells within the injected tumor while simultaneously activating a systemic, antigen-specific immune response to attack metastatic sites throughout the body. Its lead product candidate, INT230-6, is being evaluated in clinical trials for various cancers, including breast cancer and sarcomas. The company's mission is to extend patient survival and improve quality of life while preventing disease recurrence.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all INTENSITY THERAPEUTICS, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for INTENSITY THERAPEUTICS, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for INTENSITY THERAPEUTICS, INC. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Advancing high-grade copper and precious metal projects from discovery to production.
Canada COR
Cantargia Logo
Develops antibody treatments targeting IL1RAP for cancer and autoimmune/inflammatory diseases.
Sweden CANTA
Captor Therapeutics S.A. Logo
Developing TPD therapeutics for oncology and autoimmune diseases with its Optigrade™ platform.
Poland CTX
Cardiff Oncology, Inc. Logo
Clinical-stage biotech developing a PLK1 inhibitor to treat resistant cancers.
United States of America CRDF
Cardio Diagnostics Holdings, Inc. Logo
AI-powered epigenetic and genetic tests for early detection of heart disease risk.
United States of America CDIO
Cardiol Therapeutics Inc. Logo
Develops oral cannabidiol therapies for inflammatory and fibrotic heart diseases.
United States of America CRDL
CareDx, Inc. Logo
Precision diagnostics and surveillance solutions for the organ transplant journey.
United States of America CDNA
Offers one-stop BPO, CRM, and staffing for admin, manufacturing, and logistics.
Japan 6070
Caris Life Sciences, Inc. Logo
Pioneering precision cancer care via AI-powered molecular profiling and diagnostics.
United States of America CAI
Carna Biosciences, Inc. Logo
Develops kinase inhibitor drugs for oncology/autoimmune diseases & offers discovery support services.
Japan 4572

Talk to a Data Expert

Have a question? We'll get back to you promptly.